Morgan Stanley
INKT icon

Morgan Stanley’s MiNK Therapeutics INKT Stock Holding History

Morgan Stanley’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32K Buy
113
+9
+9% +$105 ﹤0.01% 7471
2026
Q1 		$1.09K Hold
104
– – ﹤0.01% 7421
2025
Q4 		$1.16K Sell
104
-11
-10% -$142 ﹤0.01% 7339
2025
Q3 		$1.61K Buy
115
+93
+423% +$1.49K ﹤0.01% 7345
2025
Q2 		$163 Sell
22
-2
-8% -$15 ﹤0.01% 7597
2025
Q1 		$208 Sell
24
-9
-27% -$80 ﹤0.01% 7468
2024
Q4 		$233 Sell
33
-1
-3% -$7 ﹤0.01% 7402
2024
Q3 		$252 Sell
34
-4
-11% -$34 ﹤0.01% 7367
2024
Q2 		$363 Sell
38
-22
-37% -$214 ﹤0.01% 7257
2024
Q1 		$545 Sell
60
-389
-87% -$3.61K ﹤0.01% 7232
2023
Q4 		$4.8K Sell
449
-361
-45% -$3.77K ﹤0.01% 6840
2023
Q3 		$8.91K Sell
810
-409
-34% -$6.66K ﹤0.01% 6771
2023
Q2 		$25.6K Buy
+1,219
New +$24.4K ﹤0.01% 6483
2023
Q1 		– Sell
-4
Closed -$107 – 7771
2022
Q4 		$107 Hold
4
– – ﹤0.01% 7691
2022
Q3 		$0 Sell
4
-42
-91% -$827 ﹤0.01% 7792
2022
Q2 		$1K Buy
46
+37
+411% +$697 ﹤0.01% 7685
2022
Q1 		$0 Sell
9
-4,248
-100% -$128K ﹤0.01% 8033
2021
Q4 		$189K Buy
+4,257
New +$506K ﹤0.01% 6107

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Morgan Stanley's INKT Position: Q2 2026 in Review

Morgan Stanley increased its MiNK Therapeutics (INKT) stake by 8.7% in Q2 2026, buying an estimated $105 and bringing the position to 113 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #7471.

Morgan Stanley first reported a position in INKT in Q4 2021 and has held it in 18 quarters since. The position peaked at $189K in Q4 2021. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Morgan Stanley held 113 shares of MiNK Therapeutics worth $1.32K as of Q2 2026.
  • Morgan Stanley bought 9 MiNK Therapeutics shares in Q2 2026, an estimated $105.
  • MiNK Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7471 holding.
  • Morgan Stanley first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Morgan Stanley's MiNK Therapeutics position peaked at $189K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.